Operating Income (Loss) of Verve Therapeutics, Inc. from 31 Dec 2019 to 31 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Verve Therapeutics, Inc. quarterly and annual Operating Income (Loss) in USD history and change rate from 31 Dec 2019 to 31 Mar 2025.
  • Verve Therapeutics, Inc. Operating Income (Loss) for the quarter ending 31 Mar 2025 was $36,636,000, a 36% increase year-over-year.
  • Verve Therapeutics, Inc. Operating Income (Loss) for the twelve months ending 31 Mar 2025 was $208,452,000, a 6% increase year-over-year.
  • Verve Therapeutics, Inc. annual Operating Income (Loss) for 2024 was $228,660,000, a 2.5% decline from 2023.
  • Verve Therapeutics, Inc. annual Operating Income (Loss) for 2023 was $223,124,000, a 35% decline from 2022.
  • Verve Therapeutics, Inc. annual Operating Income (Loss) for 2022 was $165,687,000, a 90% decline from 2021.
Source SEC data
View on sec.gov
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

Verve Therapeutics, Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $208,452,000 $36,636,000 +$20,208,000 +36% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $228,660,000 $56,067,000 -$2,119,000 -3.9% 01 Oct 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
Q3 2024 $226,541,000 $56,910,000 -$4,576,000 -8.7% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2024 2024 Q3
Q2 2024 $221,965,000 $58,839,000 -$256,000 -0.44% 01 Apr 2024 30 Jun 2024 10-Q 08 Aug 2024 2024 Q2
Q1 2024 $221,709,000 $56,844,000 +$1,415,000 +2.4% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q4 2023 $223,124,000 $53,948,000 -$6,238,000 -13% 01 Oct 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
Q3 2023 $216,886,000 $52,334,000 -$8,474,000 -19% 01 Jul 2023 30 Sep 2023 10-Q 05 Nov 2024 2024 Q3
Q2 2023 $208,412,000 $58,583,000 -$16,391,000 -39% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $192,021,000 $58,259,000 -$26,334,000 -82% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q4 2022 $165,687,000 $47,710,000 -$15,170,000 -47% 01 Oct 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
Q3 2022 $150,517,000 $43,860,000 -$20,358,000 -87% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $130,159,000 $42,192,000 -$25,228,000 -149% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $104,931,000 $31,925,000 -$17,864,000 -127% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q4 2021 $87,067,000 $32,540,000 01 Oct 2021 31 Dec 2021 10-K 27 Feb 2024 2023 FY
Q3 2021 $23,502,000 -$14,530,000 -162% 01 Jul 2021 30 Sep 2021 10-Q 07 Nov 2022 2022 Q3
Q2 2021 $16,964,000 -$10,278,000 -154% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $14,061,000 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q3 2020 $8,972,000 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $6,686,000 01 Apr 2020 30 Jun 2020 10-Q/A 16 Aug 2021 2021 Q2

Verve Therapeutics, Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $228,660,000 -$5,536,000 -2.5% 01 Jan 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
2023 $223,124,000 -$57,437,000 -35% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
2022 $165,687,000 -$78,620,000 -90% 01 Jan 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
2021 $87,067,000 -$46,440,000 -114% 01 Jan 2021 31 Dec 2021 10-K 27 Feb 2024 2023 FY
2020 $40,627,000 -$26,985,000 -198% 01 Jan 2020 31 Dec 2020 10-K 02 Mar 2023 2022 FY
2019 $13,642,000 01 Jan 2019 31 Dec 2019 10-K 14 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.